I am a former full-time member of the Sawyers laboratory, currently a research affiliate of the laboratory in my role as a clinical/translational investigator in the Genitourinary Oncology Service. My research is focused on understanding biological drivers of advanced prostate cancer in order to develop targeted clinical trials. I do this in large part through molecular profiling, including genomic analysis, of patient-derived biospecimens. I collaborate with laboratory colleagues to develop laboratory models of disease subsets that can serve as tools to understand mechanisms of resistance and drug targeting. I also oversee an institutional prostate cancer biospecimen and clinical data usage committee that aims to facilitate collaborative research using patient-derived samples and data across disciplines at MSKCC, with the ultimate goal of advancing our understanding of the disease and developing new therapies.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Wassim Abida discloses the following relationships and financial interests:
-
Clinical Education Alliance, LLC
Professional Services and Activities -
Janssen Oncology, Inc.
Professional Services and Activities -
Laekna Limited
Professional Services and Activities -
MOMA Therapeutics, Inc.
Professional Services and Activities -
Nuvation Bio, Inc.
Professional Services and Activities (Uncompensated)
-
Pfizer, Inc.
Professional Services and Activities -
TheMednet, LLC
Professional Services and Activities -
TransThera Sciences (US), Inc.
Professional Services and Activities (Uncompensated) -
UptoDate
Intellectual Property Rights
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures
